{"disease":{"id":"soft-tissue","name":"soft tissue"},"drugs":{"marketed":[{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Soft Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic soft tissue sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tasonermin","indication_name":"Sarcoma of soft tissue","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Beromun","generic_name":"TASONERMIN","company_name":"Boehringer Ingelheim International GmbH","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"yondelis","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yondelis","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase Src, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"trabectedin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yondelis","generic_name":"TRABECTEDIN","company_name":"Janssen Prods","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase Src","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Yondelis works by binding to DNA and causing interstrand crosslinks, thereby inhibiting cancer cell growth."},{"drug_id":"olaratumab","indication_name":"Sarcoma of soft tissue","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lartruvo","generic_name":"OLARATUMAB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Platelet-derived growth factor receptor alpha","drug_class":"Platelet-derived Growth Factor Receptor alpha Antagonist","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic soft tissue sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"adriacin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"votrient","indication_name":"Sarcoma of soft tissue","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Votrient","company_name":"Tracon Pharmaceuticals Inc.","drug_phase":"marketed","molecular_target":"Bone morphogenetic protein receptor type-1B, Cyclin-dependent kinase 11A, Cyclin-dependent kinase 11B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"bicillin-c-r","indication_name":"Skin and soft-tissue infections due to susceptible streptococci","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bicillin C-R","generic_name":"Penicillin G Benzathine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cell-wall peptidoglycan biosynthesis","drug_class":"Beta-lactam antibiotic","quality_score":10,"revenue":null,"mechanism":"Penicillin G inhibits bacterial cell-wall peptidoglycan biosynthesis, rendering the cell wall osmotically unstable."},{"drug_id":"liposomal-doxorubicin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"doxorubicin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"hydroxydaunomycin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":15,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05423756","title":"INSPIRE Trial for Skin and Soft Tissue Infections","phase":"NA","overall_status":"COMPLETED","enrollment_count":118562,"lead_sponsor_name":"Harvard Pilgrim Health Care","has_results":true},{"nct_id":"NCT05247333","title":"Implementation of a Minor Ailment Service in Community Pharmacy Practice","phase":"NA","overall_status":"COMPLETED","enrollment_count":20987,"lead_sponsor_name":"Universidad de Granada","has_results":false},{"nct_id":"NCT05468970","title":"Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT04181970","title":"Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Grupo Espanol de Investigacion en Sarcomas","has_results":false},{"nct_id":"NCT03244020","title":"LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology","phase":"PHASE4","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2868,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03363971","title":"Treatment of Posttraumatic Swelling and Pain With Zhi Kang Capsule","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":2200,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06526897","title":"Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1582,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT02677961","title":"An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT07489274","title":"Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial).","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":1480,"lead_sponsor_name":"Ole Hyldegaard","has_results":false},{"nct_id":"NCT04094818","title":"TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis","phase":"","overall_status":"COMPLETED","enrollment_count":1441,"lead_sponsor_name":"Inflammatix","has_results":false},{"nct_id":"NCT05697198","title":"PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine","phase":"","overall_status":"COMPLETED","enrollment_count":1429,"lead_sponsor_name":"Labcorp Corporation of America Holdings, Inc","has_results":false},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03793166","title":"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1175,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05116956","title":"SKin and Soft Tissue Necrotizing INfections in the Intensive Care Unit: a Prospective Multi-national Cohort Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1033,"lead_sponsor_name":"Henri Mondor University Hospital","has_results":false},{"nct_id":"NCT06126263","title":"Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"National Institutes of Health Clinical Center (CC)","has_results":false},{"nct_id":"NCT07417982","title":"Patients With Necrotizing Skin and Soft Tissue Infections Managed Within the SURFAST Care Pathway.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05851430","title":"Galvanize Prospective/Retrospective Pulsed Electric Field Device Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Galvanize Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05171413","title":"Predictive Models of Treatment Responses and Survival Outcomes in Patients With Soft Tissue Sarcoma","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT07432932","title":"Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT04394052","title":"Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II","phase":"","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT04393909","title":"Improving Safety of Diagnosis and Therapy in the Inpatient Setting","phase":"NA","overall_status":"COMPLETED","enrollment_count":700,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04669704","title":"Effectiveness of a Tele-Rehabilitation Evidence-based Tablet App for Rehabilitation in Traumatic Bone and Soft Injuries of the Hand, Wrist and Fingers.","phase":"NA","overall_status":"COMPLETED","enrollment_count":663,"lead_sponsor_name":"University of Seville","has_results":false},{"nct_id":"NCT01231906","title":"Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":642,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT03784014","title":"Molecular Profiling of Advanced Soft-tissue Sarcomas","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":603,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT02600611","title":"Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Motif Bio","has_results":true},{"nct_id":"NCT00346164","title":"Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":588,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT03744741","title":"HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study","phase":"","overall_status":"COMPLETED","enrollment_count":585,"lead_sponsor_name":"Inflammatix","has_results":false},{"nct_id":"NCT01710176","title":"Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":550,"lead_sponsor_name":"Italian Sarcoma Group","has_results":false},{"nct_id":"NCT03284320","title":"Retrospective Study in Sarcoma Patients","phase":"","overall_status":"COMPLETED","enrollment_count":514,"lead_sponsor_name":"University Medicine Greifswald","has_results":false},{"nct_id":"NCT02793050","title":"Retrospective Study of Trabectedin in Soft Tissue Sarcomas","phase":"","overall_status":"COMPLETED","enrollment_count":510,"lead_sponsor_name":"Italian Sarcoma Group","has_results":false},{"nct_id":"NCT02451943","title":"A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":509,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT04671693","title":"A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT05328258","title":"Use of GnRHa During Chemotherapy for Fertility Protection","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Kenny Rodriguez-Wallberg","has_results":false},{"nct_id":"NCT00354835","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":481,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT07107555","title":"Necrotizing Soft Tissue Infections","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":480,"lead_sponsor_name":"European Society for Trauma and Emergency Surgery","has_results":false},{"nct_id":"NCT03826667","title":"PMCF Study on PEEK Suture Anchors for Shoulder Indications","phase":"","overall_status":"COMPLETED","enrollment_count":464,"lead_sponsor_name":"Smith & Nephew, Inc.","has_results":true},{"nct_id":"NCT01327885","title":"Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":452,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT06967961","title":"Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Institut Claudius Regaud","has_results":false},{"nct_id":"NCT06699576","title":"ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":448,"lead_sponsor_name":"Hansoh BioMedical R&D Company","has_results":false},{"nct_id":"NCT05108298","title":"Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Eastern Cooperative Oncology Group","has_results":false},{"nct_id":"NCT02192333","title":"Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors","phase":"NA","overall_status":"COMPLETED","enrollment_count":390,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT03375437","title":"RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":376,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT06422806","title":"Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":365,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05824975","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT05075993","title":"Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":352,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03452644","title":"US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":350,"lead_sponsor_name":"Istituto Ortopedico Rizzoli","has_results":false},{"nct_id":"NCT06068075","title":"Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD","phase":"NA","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT04216953","title":"MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":320,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT04198571","title":"Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries","phase":"","overall_status":"COMPLETED","enrollment_count":317,"lead_sponsor_name":"Pfizer","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}